Take 20 Years Off Your Age

Dr. Daniel Rudman's study in the New England Journal of Medicine represented the biggest breakthrough in anti-aging medicine at the time and led to a wide acceptance that, "The overall deterioration of the body that comes with growing old is not inevitable."

Dr. Rudman studied men between the ages of 61 and 80 who were overweight. These men did not alter their diet, exercise, or smoking habits. When they were given HGH, they gained an average of 8.8% in lean muscle mass while losing 14% of their body fat. They experienced localized increases in bone density and their skin became thicker and firmer. The subjects of this study reversed these parameters of aging by 10-20 years.

Look at these amazing test Results

Results from a study: (Effects of Growth Hormone administration on 202 patients ages 39-74) L. Casserry M.D., Phd and Edmund Chein, M.D. Medical College of Wisconsin and Palm Springs Life Extension Institute.

The anabolic actions of GH in GH-deficient adults and children are well documented. Replacement with GH in such individuals promotes protein synthesis and reduces irreversible loss of protein through oxidation. Although GH is known to be self-administered by athletes, its protein metabolic effects in this context are unknown. This study was designed to determine whether 4 wk of high dose recombinant human GH(r-hGH) administration altered whole body leucine kinetics in endurance-trained athletes at rest and during and after 30 min of exercise at 60% of maximal oxygen uptake.

Eleven endurance-trained male athletes were studied, six randomized to receive r-hGH (0.067 mg/kg.d), and five to receive placebo. Whole body leucine turnover was measured at rest and during and after exercise, using a 5-h primed constant infusion of 1-[(13)C] leucine, from which rates of leucine appearance (an index of protein breakdown), leucine oxidation, and nonoxidative leucine disposal (an index of protein synthesis) were estimated. Under resting conditions, r-hGH administration increased rate of leucine appearance and nonoxidative leucine disposal, and reduced leucine oxidation (P < 0.01). This effect was apparent after 1 wk, and was accentuated after 4 wk, of r-hGH administration (P < 0.05). During and after exercise, GH attenuated the exercise-induced increase in leucine oxidation (P < 0.05). There were no changes observed in placebo-treated subjects compared with the baseline study.

We concluded that GH administration to endurance-trained athletes has a net anabolic effect on whole body protein metabolism at rest and during and after exercise.

PMID: 14602735 [PubMed - indexed for MEDLINE] J Clin Endocrinol Metab. 2003 Nov;88(11):5221-6

Beneficial Effects Of Gh/Igf-1 On Skeletal Muscle Atrophy And Function In Experimental Heart Failure


Dalla Libera L, Ravara B, Volterrani M, Gobbo V, Della Barbera M, Angelini A, Betto DD, Germinario E, Vescovo G.Internal medicine II, Ospedale S. Bortolo, Viale Rodolfi 37, 36100 Vicenza, Italy. Idl@bio.unipd.it

Muscle atrophy is a determinant of exercise capacity in heart failure (CHF). Myocyte apoptosis, triggered by tumor necrosis factor-alpha (TNF-alpha) or its second messenger sphingosine (SPH), is one of the causes of atrophy. Growth hormone (GH) improves hemodynamic and cardiac trophism in several experimental modes of CHF, but its effects on skeletal muscle in CHF in not yet clear.

We tested the hypothesis that GH can prevent skeletal muscle apoptosis in rats with CHF. CHF was induced by injecting monocrotaline. After 2 wk, 2 groups of rats were treated with GH (0.2 mg.kg-1.day-1 and 1.0 mg.kg-1.day-1) subcutaneously. A third group of controls had saline. After 2 additional weeks, rats were killed. Tibialis anterior cross-sectional area, myosin heavy chain (MHC) composition, and a study on myocyte apoptosis and serum levels of TNF-alpha and SPH were carried out. The number of apoptotic nuclei, muscle atrophy, and serum levels of TNF-alpha and SPH were decreased with GH at high but not at low doses compared with CHF rats. Bcl-2 was increased, whereas activated caspases and bax were decreased. The MHC pattern in GH-treated animals was similar to that of controls.Monocrotaline slowed down both contraction and relaxation but did not affect specific tetanic force, whereas absolute force was decreased.

GH treatment restored contraction and relaxation to control values and brought muscle mass absolute twitch and tetanic tension to normal levels. These findings may provide an insight into the therapeutic strategy of GH given to patients with CHF to improve exercise capacity.

PMID: 13679302 [PubMed - in process] Am J Physiol Cell Physiol. 2004
Jan ; 286(1):C13844. Epub 2003 Sep 17.

Scientists have long sought to determine what agent controls the production of the human growth hormone hGH, which is vital for proper physical development.

Now, in findings that point toward an eventual gene therapy for the type of dwarfism that results when the pituitary gland is unable to manufacture the hormone, scientists at the University of Pennsylvania School of Medicine have found the mechanism that sets hGH in action. In addition, they’ve discerned an unusual pattern of activation in which the key mechanism operates by remote control. Their research will appear in the Friday, February 15, issue of the journal Molecular Cell.

Working with transgenic mice, the Penn researchers were able to pinpoint the activation mechanism location called hypersensitive site 1 (HS1), within the “locus control region” 15 kilobases from the h gene. A kilobase is a measurement representing a unit of nucleic acid. Within the microscopic realm of cells, this activation is equivalent of unlocking the front door of a house from seven buildings away.

“What we found is surprising because most genes are controlled by a promoter element adjacent to the gene, or within the gene’s proximity. But in the case of this human growth hormone, the controlling mechanism is so far away there is an intervening gene between hGH and the activation site,” said Stepehn Liebhaber, MD, Professor of Genetics and Medicine. He is corresponding author for the study along with Nancy Cooke, MD, Professor of Medicine in the Division of Endocrinology, Diabetes and Metabolism.

The human gene cluster containing hGH includes five separate human growth genes, four of which have importance during fetal development. Only the gene hGH functions following birth, and is necessary for normal growth: Without it, humans develop a condition called pituitary dwarfism, in which their physical stature never reaches five feet.

Liebhaber, Cooke and their colleagues at Penn have been researching hGH in a series of studies and were the first to demonstrate that, unlike most hormones, hGH cannot be “turned on” merely by activating a nearby promoter element.

In the present study, they’ve established that activating HS1 triggered a series of enzymatic changes spanning the layer of proteins and DNA (chromatin) that separate the hypersensitive activation site from the hormone promoter, eventually affecting the promoter, and ultimately opening the growth hormone itself.

“The modifications migrate through the chromatin in some way that we do not yet understand,” Cooke said. Added Liebhaber, “Now we’re studying the mechanism through which this signal spreads.”

Yugong Ho, PhD, the lead author on the paper, and Felice Elefant, PhD, both post-doctoral fellowship, Penn, Liebhaber and Cooke worked on the research.

This is possible because the body produces a number of forms of hGH and while most of these are indistinguishable from the injected kind, there is a tiny amount of a smaller form which could be targeted. This test would be able to detect hGH administered within just two days of injection.

The study was funded by the National Institutes of Health’s National Institute of Child Health and Human Development.



HGH and Ovarian Treatment

The objective of this study was to evaluate whether a combined human growth hormone (HGH) and human menopausal gonadotrophin (HMG) treatment can improve ovulation induction in poor ovarian responders. Ten patients aged 28-43 years and requiring >25 ampoules of HMF for ovulation were admitted to the study. Pituitary growth hormone reserve was evaluated by clonidine stimulation and insulin tolerance tests before commencement of treatment. The patients underwent on treatment cycle with D-tryptophan-6-luteinizing hormone-releasing hormone (D-Trp6-LHRH) and HMG and another cycle with D-Trp6-LHF, HMG and HGH. Serum HGH, insulin-like growth factor (IGF)-I and oestradiol were measured throughout the two treatment cycles and ollicular maturation was assessed by ultrasonographic studies. All patients tested showed no elevation of their serum HGH concentration during a clonidine test, but showed and adequate response during insulin tolerance tests. No significant difference was found in the number of HMG ampoules, duration of treatment, number of leading follicles, and serum oestradiol concentration between the two treatment cycles. Co-treatment with HGH and HMG did not improve ovarian performance in poor ovarian responders. No correlation was found between the results of HGH pituitary function tests and the ovarian response gonadotrophins.


HGH Treatment for HIV

HIV cells attack the immune system Doctors may be able to stave off HIV by giving patients growth hormone, researchers have found. A team from the Gladstone Institute of Virology and Immunology the University of California San Francisco said the hormone could stimulate the production of immune cells and help the body fight the infection. The specific immune cells they looked at, T cells which are produced by the thymus gland, are attacked and destroyed by HIV, leaving patients unable to fight off infections linked to AIDS. In the study five male HIV patients were given daily does of growth hormone.

After six months, researchers found the number of new T cells circulating in the blood had increased significantly. The researchers say this is the first study to show how the thymus functions can be significantly enhanced by growth hormone therapy to stimulate it to produce new T cells. However, they admit the study was small and the therapy is not yet ready to be given to patients with HIV. Two out of the five also experienced side effects from the therapy. Potential adverse effects of the treatment include bone pain and abnormal bone growth, swelling in the arms and legs, carpal tunnel syndrome and even diabetes. Doctors added that the study was only preliminary, and was not intended to show whether growth hormone actually improved the health status of the patients.

Larger Trial

A larger study is planned to compare HIV- infected patients taking growth hormone with others not on the treatment. Dr. Laura Napolitano, who led the study, said: “Finding a way to stimulate the thymus produce T cells would help HIV-infected patients to preserve and restore their embattled immune systems.” She added: “The results of the current study are preliminary, but give us hope that we may be able to provide therapies to stimulate thymic function and T-cell production in individuals infected with HIV. “Additional studies need to be completed before we can conclude that growth hormone therapy provides benefit to the immune system of HIV infected patients. “We need to establish that the benefit of the therapy outweigh the risks.”

Early Days

Dr. Antonio Pires of Imperial College of London, who, alongside Dr. Nesrina Imami, has also carried out research into using growth hormone in HIV patients, told BBC News Online: “From our research we have seen that daily administration of 4mg of growth hormone induced HIV-1-specific T cell responses.” He said the changes seen were significant. “These effects disappeared with a decrease in frequency of dosing.” He added: “This is promising data. However, caution and more research is needed in order to ascertain the true benefits of growth hormone for the treatment of HIV infection.” Derek Bodell, chief executive of the National Aids Trust (NAT), said: “We welcome the finding that growth hormone may stimulate production of T cells to boost the body’s ability to fight HIV. “It is important to ensure that the use of growth hormone in any treatment does not have an adverse effect on the health of those who might receive the treatment.” He added: “The study clearly has a long way to go before we know if it can be beneficial for people with HIV. “Of course with more than 40 million people worldwide now living with HIV- and 5,000 diagnoses alone in the last year-it remains vital, in responding to the AIDS epidemic, that we look at all new opportunities to defeat the disease. This may come in the form of a variety of new treatments or vaccines. “The study was published in the journal of Aids.


Perioperative Growth Hormone Treatment Increases Nitrogen and Fluid Balance and results in short-term and long-term conservation of lean tissue.

The surgical procedure for forming an ileoanal anastomosis with a J pouch usually involves a temporary ileostomy. Patients undergoing IAA surgery thus need to recover quickly because they return for ileostomy closure three months later. We evaluated the effects of perioperative biosynthetic growth hormone treatment of short and long term changes in body composition and on nutrition intake. Patients with ulcerative colitis undergoing IAA surgery were randomly assigned to double-blind treatment with placebo (n=12) or 6 IU GH twice daily (n=12) from two days before to seven days after the operation. Examinations were from two days before to nine days after the operation and on days 30 and 90. Body composition was assessed with a dual-energy X-ray absorptiometry scanner. The two groups had similar nutritional intakes. On postoperative day seven, placebo-treated patients had lost 4.2 kg (95% CI; 3.0, 5.4) total tissue mass, 3.6 kg (2.1, 5.1) lean tissue mass, and 0.5 kg (-0.1, 1.2) fat mass. These reductions persisted three months later. Compared with placebo, GH improved nitrogen balance, changes in lean tissue mass (gain of 3.2 kg (1.6, 4.9), P=0.001 but increased the loss of fat mass (loss of 0.7 kg (0.0, 1.5), P=0.049) on postoperative day seven. Three months later, the placebo-treated patients had lost 2.4 kg (0.7, 4.2) more lean tissue mass than GH-treated patients (P=0.009 whereas changes in total tissue and fat mass were not significantly different. Hence, GH treatment enhanced the long-term regain of tissue mass.

According to Dr. Ronald Klatz and Dr. Robert Goldman of the American Academy to Anti-Aging Medicine, HGH “reduced body fat by 14.4 percent after six months, without dieting.” Increased Muscle Mass- Dr. Klatz and Dr. Goldman also stated HGH causes “an average gain of 8.8 percent in muscle mass after six months, without exercise.”

Anti-Aging Research and HGH Studies

Levels of HGH peak during adolescence. After age 21, HGH levels fall about 14% per decade. This means after age 50, more than 50% of us are either partially or completely deficient in HGH.

The decline of HGH, however, is neither irreparable nor permanent, because we can now control our hormone levels. HGH may well be the proverbial fountain of youth. Thousand of studies confirm that raising HGH levels can help prevent and even reverse the aging process.

Dr. Michael Fossel, a clinical professor of medicine at Michigan State University, the editor of the Journal of Anti-Aging Medicine and author of Reversing Human Aging, is convinced that our lifespan could reach as high as 200 years. According to him “Aging is not wear and tear, but wear and tear unleashed.”

Read the full story HERE

Dr. Robert M. Goldman, President of the National Academy of Sports Medicine, has spoken in national conferences about how anti-aging medicine is “the future of medical practice” and how it “allows both the medical professional and patient to have control over their personal health and well being, and the quality of their fitness and life functions.”

He also says that “we have 70 year old bodies of those less than half their age,” and that with the rate of advancement of this fascinating new science, we can be increasingly healthier and more youthful people as we age in years, Dr. Goldman said, “Anti-aging medicine is the future of medical practice. It encompasses all specialties and fields. It can be accessed and utilized by everyone.”

In a study performed by L. Cass Terry, M.D., Ph.D., when the levels of HGH were elevated, over 75 of his patients experienced body-fat loss, muscle-mass gain, greater strength, increased exercise tolerance and energy levels and an improved quality of life. A large majority also reported better skin texture and greater skin thickness and elasticity.

Daniel Rudman, M.D. and his colleagues at the Medical College of Wisconsin, administered HGH to a group of men between the ages of 61-80. They found that within six months, without any change in diet, exercise, or smoking habits, the men lost 14% of their body-fat and gained an average of 8.8% muscle mass.

HGH Studies

The declining activity of the growth hormone-insulin-like growth factor 1 (IGF-1) axis with advancing age may contribute to the decrease in lean body mass and the increase in mass of adipose tissue that occurs with aging.

Methods. To test this hypothesis, we studied IGF-1 plasma with 21 healthy men from 61 to 81 years old who had plasma IGF-1 concentrations of less than 350 U per liter during a six-month base-line period and a six-month treatment period that followed. During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic human growth hormone per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment. Plasma IGF-1 levels were measured monthly. At the end of each period, we measured lean body mass, the mass of adipose tissue, skin thickness (epidermis plus dermis), and bone density at nine skeletal sites.

1990 Dr. Daniel Rudman Study

New England Journal of Medicine, Volume 323 July 5, 1990 Number 1

Effects of Human Growth Hormone in Men over 60 Years Old. Daniel Rudman, M.D., Axel G. Feller, M.D., Hoskote S. Nagraj, M.D., Gregory A. Gergans, M.D., Pardee Y. Lalitha, M.D., Allen F. Goldberg, D.D.S., Robert A. Schlenker, Ph.D., Lester Cohn, M.D., Inge W. Rudman, B.S., and Dale E. Mattson, Ph.D.